Stacy L. Taylor - Jun 30, 2021 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)

Role: SVP and General Counsel
Signature: /s/ Stacy L. Taylor by Eric Billings as attorney-in-fact
Stock symbol: ADPT
Transactions as of: Jun 30, 2021
Transactions value $: -$109,951
Form type: 4
Date filed: 7/1/2021, 09:00 PM
Previous filing: Jun 21, 2021
Next filing: Sep 9, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ADPT	Common Stock	Options Exercise	$8.13K	+1.04K	+6.93%	$7.80	16.1K	Jun 30, 2021	Direct	F1
transaction	ADPT	Common Stock	Options Exercise	$11.6K	+1.77K	+11.02%	$6.55	17.8K	Jun 30, 2021	Direct	F1
transaction	ADPT	Common Stock	Options Exercise	$42.9K	+1.35K	+7.59%	$31.71^*	19.2K	Jun 30, 2021	Direct	F1
transaction	ADPT	Common Stock	Sale	-$156K	-3.77K	-19.64%	$41.35^*	15.4K	Jun 30, 2021	Direct	F1, F2
transaction	ADPT	Common Stock	Sale	-$16.6K	-395	-2.56%	$42.13^*	15K	Jun 30, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADPT	Stock Option (Right to Buy)	Options Exercise	$0	-1.04K	-4.35%	$0.00	22.9K	Jun 30, 2021	Common Stock	1.04K	$7.80	Direct	F1, F3
transaction	ADPT	Stock Option (Right to Buy)	Options Exercise	$0	-1.77K	-10%	$0.00	15.9K	Jun 30, 2021	Common Stock	1.77K	$6.55	Direct	F1, F4
transaction	ADPT	Stock Option (Right to Buy)	Options Exercise	$0	-1.35K	-3.03%	$0.00	43.3K	Jun 30, 2021	Common Stock	1.35K	$31.71	Direct	F1, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.
F2	The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $41.00 to 41.58, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3	The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F4	The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F5	The options vested with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.